Generated by AI
Summary of Oct 9's posts. Generated by AI.
Summary of Mar 23's posts. Generated by AI.
Summary of Dec 21's posts. Generated by AI.
Summary of Sep 29's posts. Generated by AI.
Investors talking about ALDX also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.
Aldeyra Therapeutics, Inc. is a biotechnology company focused on discovering and developing therapies for immune-mediated diseases. Its current pipeline centers on small-molecule and related drug candidates for ophthalmology and other inflammatory conditions, including reproxalap for dry eye disease and allergic conjunctivitis, ADX-2191 for selected retinal disorders, and ADX-629 for several immune-related indications. The company also advances preclinical reactive aldehyde species modulator programs aimed at addressing systemic and retinal diseases. Aldeyra Therapeutics emphasizes treatments designed to modulate inflammatory pathways and improve patient care across eye disease, allergy, and broader immune-mediated segments. Based in Lexington, Massachusetts, Aldeyra Therapeutics operates as a clinical-stage biopharmaceutical developer with a portfolio positioned across multiple therapeutic areas and specialty markets.
Website131 Hartwell Avenue
Lexington, MA, 02421
United States